TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from TOT BIOPHARM International Co. Ltd. ( (HK:1875) ) is now available.
TOT BIOPHARM International Co. Ltd. successfully passed all proposed resolutions at its Annual General Meeting held on June 20, 2025. These resolutions included the approval of financial statements, re-election of directors, and granting of mandates for share allotment and buyback, indicating strong shareholder support and strategic alignment for future corporate governance and operational strategies.
The most recent analyst rating on (HK:1875) stock is a Buy with a HK$3.00 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.
More about TOT BIOPHARM International Co. Ltd.
TOT BIOPHARM International Co. Ltd. is a biopharmaceutical company incorporated in Hong Kong. It focuses on the development, manufacturing, and commercialization of oncology drugs, aiming to provide innovative therapies for cancer treatment.
Average Trading Volume: 142,312
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.55B
Learn more about 1875 stock on TipRanks’ Stock Analysis page.